TCTR20240509002尚未招募3 期
Efficacy of 4-week Mosapride compared to Domperidone with twice daily Proton pump inhibitor in Systemic Sclerosis patients with Gastro-esophageal Reflux Disease
Thai Rheumatism Association0 个研究点目标入组 160 人开始时间: 2024年5月9日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Patients diagnosed with systemic sclerosis based on the 2013 American College of Rheumatology/The European Alliance of Associations for Rheumatology (ACR/EULAR) criteria
- •2. Patients aged 18 years or older
- •3. Patients diagnosed with newly diagnosed gastroesophageal reflux disease (GERD) with a GERD-Q score greater than or equal to 8 points, and when treated with omeprazole, 20 mg twice daily before breakfast and dinner, still have a GERD-Q score greater than or equal to 8 points, or patients diagnosed with GERD who have been treated with omeprazole, 20 mg twice daily before breakfast and dinner, and still have a GERD-Q score greater than or equal to 8 points
- •4. Patients who have not received prokinetic drugs for at least 2 weeks prior to baseline assessment before starting the study
- •5. If patients were previously taking domperidone (in cases diagnosed with GERD previously treated with omeprazole and domperidone), they will enter a wash-out period lasting 2 weeks and may still qualify for study participation
排除标准
- •1. Pregnant individuals (in cases where female volunteers still menstruate, pregnancy testing will be conducted before considering enrollment in the research project)
- •2. Breastfeeding individuals
- •3. Individuals with a history of surgery in the esophagus or stomach
- •4. Individuals with a history of upper gastrointestinal endoscopy procedure
- •5. Individuals with a history of upper gastrointestinal endoscopy showing Barrett's esophagus
- •6. Bedridden individuals who cannot assist themselves
- •7. Individuals with active cancer
- •8. Individuals with chronic diseases that are difficult to control or severe, such as asthma at any stage, chronic obstructive pulmonary disease (COPD) at any stage, acute and chronic ischemic heart disease not treated with revascularization, acute and chronic heart failure, Child-Pugh class B-C liver cirrhosis, stage 4-5 chronic kidney disease
- •9. Individuals with acute infections, including acute bacterial infections, acute viral infections, tuberculosis and other non-tuberculous mycobacterial infections under treatment, invasive fungal infections (e.g., bloodstream infections, pulmonary infections) under treatment
- •10. Individuals with mental illness who cannot control their symptoms
- •11. Individuals with a history of severe food allergies (anaphylaxis) that may cause gastrointestinal side effects
- •12. Individuals with a history of medication that may affect the evaluation of GERD symptoms (e.g., non-steroidal anti-inflammatory drugs, tetracycline antibiotics, isoniazid, iron supplements, digoxin, bisphosphonates)
- •13. Individuals with chewing difficulties
- •14. Individuals with a history of head and neck radiation therapy
- •15. Individuals with abnormal sensations in the chest area (e.g., nerve related chest pain radiating along the chest wall)
- •16. Individuals diagnosed with Celiac disease
- •17. Individuals with a history of abnormal heart electrical activity in the form of QT prolongation (male volunteers QTc more than or equal to 450 msec, female volunteers more than or equal to 460 msec)
研究者
相似试验
Unknown
3 期
The efficacy and safety of mosapride compared with domperidone in Parkinson's disease with gastroparesis; A randomized, double blind, double dummy studyGastroparesis in Parkinsons diseaseParkinsons diseaseGastric emptying timeMosaprideDomperidoneProkineticGastroparesisTCTR20220821001Faculty of Medicine, Prince of Songkla University60
已完成
不适用
Efficacy of mosapride citrate with a split dose of PEG+ascorbic acid for bowel preparation in elderly patientsKCT0002580Inje University Haeundae Paik Hospital280
已完成
4 期
Comparative Efficacy of Omeprazole plus Mosapride Combination Therapy versus Omeprazole Monotherapy in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease: a randomized controlled trialproton pump inhibitor refractory gastroesophageal reflux diseasemosaprideproton pump inhibitorgastroesophageal reflux diseasecombined therapyTCTR20190418003Rajavithi Hospital44
已完成
不适用
The comparison on effectiveness between mopride and acotiamide in the functional dyspepsia patientsfunctional dyspepsiaJPRN-UMIN000024049Kawasaki Medical School100
招募中
不适用
A randomized, prospective, double-blind clinical trial of the effect of mosapride in patients with small intestinal bacterial overgrowthDiseases of the digestive systemKCT0004994The Catholic University of Korea, St. Vincent's Hospital87